MedTrace Logo

Control of Asthma Patients Symptomatic on Inhaled Corticosteroids

NCT00330070 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2007-02-16

No results posted yet for this study

Summary

The purpose of the study is to determine whether IPL512,602 is safe and effective for the treatment of asthma symptoms in patients who remain symptomatic on a background therapy of inhaled corticosteroids.

Conditions

Interventions

DRUG

IPL512,602 20 mg once daily

DRUG

IPL512,602 Matching Placebo once daily

Sponsors & Collaborators

  • Inflazyme Pharmaceuticals Ltd

    lead INDUSTRY

Principal Investigators

  • Busse William, MD · University of Wisconsin, Madison

  • Jonathan Corren, MD · Allergy Research Foundatin, Inc.

  • Alan Heller, MD · San Jose Clinical Research

  • Edward Kerwin, MD · Clinical Research Institute of South Oregon

  • Y. Hsu, MD · West Coast Clinical Trials

  • Eli Meltzer, MD · Allergy and Asthma Medical Group

  • S. David Miller, MD · Northeast Medical Research Associates

  • Michael J Noonan · Allergy Associates Research Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00330070 on ClinicalTrials.gov